For instance, increased expression levels of SEMA4D, SELE, and SLC4A4 were linked to the higher sensitivity of cancer cells to a variety of chemotherapeutic drugs including nelarabine, megestrol acetate, isotretinoin, palbociclib, ibrutinib, etc. In addition, the high expression of CCL22 and RGS16 was related to greater drug resistance of cancer cells to midostaurin, ixazomib citrate, and dasatinib (Figure 8). Here, SLC4A4 is linked to cancer.